934 research outputs found

    Care-seeking dynamics among patients with diabetes mellitus and hypertension in selected rural settings in Kenya

    Get PDF
    Diabetes mellitus and hypertension are two common non-communicable diseases (NCDs) that often coexist in patients. However, health-seeking behaviour in patients with diabetes mellitus or hypertension has not been extensively studied especially in low- and middle-income countries. This study aimed to examine care-seeking dynamics among participants diagnosed with diabetes and/or hypertension across nine counties in rural Kenya. We conducted a cross-sectional study among adults diagnosed with diabetes and/or hypertension through face-to-face interviews. Of the 1100 participants, 69.9% had hypertension, 15.5% diabetes while 14.7% had both. The mean age of the respondents was 64 years. The majority of the respondents (86%) were on allopathic treatment. Hospital admission, having a good self-rated health status and having social support for illness, were positively associated with appropriate health-seeking behaviour while use of alcohol and pharmacy or chemist as source of treatment were negatively associated with appropriate health-seeking behaviour. Our study found a high prevalence of appropriate health-seeking behaviour among respondents with the majority obtaining care from government facilities. The results are evidence that improving public health care services can promote appropriate health-seeking behaviour for non-communicable diseases and thus improve health outcomes

    Cervical dystonia incidence and diagnostic delay in a multiethnic population.

    Get PDF
    BackgroundCurrent cervical dystonia (CD) incidence estimates are based on small numbers in relatively ethnically homogenous populations. The frequency and consequences of delayed CD diagnosis is poorly characterized.ObjectivesTo determine CD incidence and characterize CD diagnostic delay within a large, multiethnic integrated health maintenance organization.MethodsWe identified incident CD cases using electronic medical records and multistage screening of more than 3 million Kaiser Permanente Northern California members from January 1, 2003, to December 31, 2007. A final diagnosis was made by movement disorders specialist consensus. Diagnostic delay was measured by questionnaire and health utilization data. Incidence rates were estimated assuming a Poisson distribution of cases and directly standardized to the 2000 U.S. census. Multivariate logistic regression models were employed to assess diagnoses and behaviors preceding CD compared with matched controls, adjusting for age, sex, and membership duration.ResultsCD incidence was 1.18/100,000 person-years (95% confidence interval [CI], 0.35-2.0; women, 1.81; men, 0.52) based on 200 cases over 15.4 million person-years. Incidence increased with age. Half of the CD patients interviewed reported diagnostic delay. Diagnoses more common in CD patients before the index date included essential tremor (odds ratio [OR] 68.1; 95% CI, 28.2-164.5), cervical disc disease (OR 3.83; 95% CI, 2.8-5.2), neck sprain/strain (OR 2.77; 95% CI, 1.99-3.62), anxiety (OR 2.24; 95% CI, 1.63-3.11) and depression (OR 1.94; 95% CI, 1.4-2.68).ConclusionsCD incidence is greater in women and increases with age. Diagnostic delay is common and associated with adverse effects. © 2019 International Parkinson and Movement Disorder Society

    The Lantern Vol. 16, No. 2, December 1947

    Get PDF
    • A Little Light • Traitor\u27s Son • The Comeback • Wolf-Dog • Lucky Harry • Security or Progress • To Tell a Story • Endless • What Purpose, Life? • I Would Not Say • Adult Farewell • Springtime Fields • M.W. Armstronghttps://digitalcommons.ursinus.edu/lantern/1044/thumbnail.jp

    The Lantern Vol. 15, No. 2, Spring 1947

    Get PDF
    • Midsummer Afternoon\u27s Dream • Lost Love • The Rocket • Speak Now--- • Unique Experience • The Exile • Chronology • Procrustean Dike • A Faeble • The Paris Story • Inspiration • Gently Spoken • On Shavinghttps://digitalcommons.ursinus.edu/lantern/1041/thumbnail.jp

    Metallicity of solar-type stars with debris discs and planets

    Full text link
    Around 16% of the solar-like stars in our neighbourhood show IR-excesses due to debris discs and a fraction of them are known to host planets. We aim to determine in a homogeneous way the metallicity of a sample of stars with known debris discs and planets. Our analysis includes the calculation of the fundamental stellar parameters by applying the iron ionisation equilibrium conditions to several isolated Fe I and Fe II lines. The metallicity distributions of the different stellar samples suggest that there is a transition toward higher metallicities from stars with neither debris discs nor planets to stars hosting giant planets. Stars with debris discs and stars with neither debris nor planets follow a similar metallicity distribution, although the distribution of the first ones might be shifted towards higher metallicities. Stars with debris discs and planets have the same metallicity behaviour as stars hosting planets, irrespective of whether the planets are low-mass or gas giants. In the case of debris discs and giant planets, the planets are usually cool, -semimajor axis larger than 0.1 AU. The data also suggest that stars with debris discs and cool giant planets tend to have a low dust luminosity, and are among the less luminous debris discs known. We also find evidence of an anticorrelation between the luminosity of the dust and the planet eccentricity. Our data show that the presence of planets, not the debris disc, correlates with the stellar metallicity. The results confirm that core-accretion models represent suitable scenarios for debris disc and planet formation. Dynamical instabilities produced by eccentric giant planets could explain the suggested dust luminosity trends observed for stars with debris discs and planets.Comment: Accepted for publication by A&A, 17 pages, 10 figure

    The Lantern Vol. 16, No. 1, Fall 1947

    Get PDF
    • A Little Light • Social Solidarity • The Struggle • 1949 Report • Blues • Angel\u27s Wings • Street Death • The Giant • Not Alone • B or Something • After Argument • Friendship • Built That Way • The Passing • Freshman • Asleep • John J. Heilemannhttps://digitalcommons.ursinus.edu/lantern/1043/thumbnail.jp

    Predictive value of cardiac magnetic resonance right ventricular longitudinal strain in patients with suspected myocarditis

    Get PDF
    BACKGROUND Recent evidence underlined the importance of right (RV) involvement in suspected myocarditis. We aim to analyze the possible incremental prognostic value from RV global longitudinal strain (GLS) by CMR. METHODS Patients referred for CMR, meeting clinical criteria for suspected myocarditis and no other cardiomyopathy were enrolled in a dual-center register cohort study. Ejection fraction (EF), GLS and tissue characteristics were assessed in both ventricles to assess their association to first major adverse cardiovascular events (MACE) including hospitalization for heart failure (HF), ventricular tachycardia (VT), recurrent myocarditis and death. RESULTS Among 659 patients (62.8% male; 48.1 ± 16.1 years), RV GLS was impaired (> - 15.4%) in 144 (21.9%) individuals, of whom 76 (58%), 108 (77.1%), 27 (18.8%) and 40 (32.8%) had impaired right ventricular ejection fraction (RVEF), impaired left ventricular ejection fraction (LVEF), RV late gadolinium enhancement (LGE) or RV edema, respectively. After a median observation time of 3.7 years, 45 (6.8%) patients were hospitalized for HF, 42 (6.4%) patients died, 33 (5%) developed VT and 16 (2.4%) had recurrent myocarditis. Impaired RV GLS was associated with MACE (HR = 1.07, 95% CI 1.04-1.10; p < 0.001), HF hospitalization (HR = 1.17, 95% CI 1.12-1.23; p < 0.001), and death (HR = 1.07, 95% CI 1.02-1.12; p = 0.004), but not with VT and recurrent myocarditis in univariate analysis. RV GLS lost its association with outcomes, when adjusted for RVEF, LVEF, LV GLS and LV LGE extent. CONCLUSION RV strain is associated with MACE, HF hospitalization and death but has neither independent nor incremental prognostic value after adjustment for RV and LV function and tissue characteristics. Therefore, assessing RV GLS in the setting of myocarditis has only limited value

    Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial

    Get PDF
    The pharmacological treatment of depression consists of stages of trial and error, with less than 40% of patients achieving remission during first medication trial. However, in a large, randomized-controlled trial (RCT) in the U.S. (“GUIDED”), significant improvements in response and remission rates were observed in patients who received treatment guided by combinatorial pharmacogenomic testing, compared to treatment-as-usual (TAU). Here we present results from the Canadian “GAPP-MDD” RCT. This 52-week, 3-arm, multi-center, participant- and rater-blinded RCT evaluated clinical outcomes among patients with depression whose treatment was guided by combinatorial pharmacogenomic testing compared to TAU. The primary outcome was symptom improvement (change in 17-item Hamilton Depression Rating Scale, HAM-D17) at week 8. Secondary outcomes included response (≥50% decrease in HAM-D17) and remission (HAM-D17 ≤ 7) at week 8. Numerically, patients in the guided-care arm had greater symptom improvement (27.6% versus 22.7%), response (30.3% versus 22.7%), and remission rates (15.7% versus 8.3%) compared to TAU, although these differences were not statistically significant. Given that the GAPP-MDD trial was ultimately underpowered to detect statistically significant differences in patient outcomes, it was assessed in parallel with the larger GUIDED RCT. We observed that relative improvements in response and remission rates were consistent between the GAPP-MDD (33.0% response, 89.0% remission) and GUIDED (31.0% response, 51.0% remission) trials. Together with GUIDED, the results from the GAPP-MDD trial indicate that combinatorial pharmacogenomic testing can be an effective tool to help guide depression treatment in the context of the Canadian healthcare setting (ClinicalTrials.gov NCT02466477)
    • …
    corecore